A 0.3 mL, 31G, 5/16 inch syringe is not the same product as a 1 mL, 29G, 1/2 inch syringe
We tested the modified Dihexa against 200 M neomycin and observed no protection, suggesting that the current form of Dihexa has a high specificity for providing protection, likely via its specific interaction with native HGF (Figure 7)
BPC157 is not intended for human or veterinary administration Research Use Only Notice This product is intended for laboratory research use only and is not approved for human or veterinary use
BPC-157 oral capsules are also available as blended capsules with TB500 for enhanced recovery and inflammation benefits
Mild temporary redness at the injection site is the most common reported side effect of the injectable
These may include mild headache, dizziness, fatigue, or slight nasal irritation